Advertisement

A Systematic Comparison of Overall Survival Between Men and Women With Triple Negative Breast Cancer

      Abstract

      Introduction

      Triple-negative breast cancer (TNBC) in men is very rare. The clinical characteristics, prognostic factors, and overall survival of men with TNBC have not been characterized.

      Methods

      The study population consisted of men and women with a diagnosis of stage I-III TNBC between 2010 and 2016 in the National Cancer Database. Baseline demographic and tumor characteristics between men and women were compared using Pearson's Chi-Square test for categorical variables and Mann-Whitney U test for continuous variables. Kaplan–Meier and multivariate Cox proportional hazards regression model was used to compare survival and identify prognostic factors.

      Results

      A total of 311 men and 95,406 women with TNBC were included in the final analysis. The 3-year and 5-year overall survival was 74.8% and 68.8% in men, while it was 83.2% and 74.8% in women, respectively. In multivariate analysis, men were found to have a significantly worse overall survival compared to women (HR, 1.49, 95% CI, 1.19-1.86, P= .01). Older age at diagnosis, higher TNM stage, undergoing mastectomy and not undergoing chemotherapy or radiation were identified as independent negative prognostic factors in men with TNBC.

      Conclusion

      In one of the largest studies of men with TNBC, men were noted to have a poorer overall survival compared to women, despite adjusting for usual prognostic factors. Further research into differences in tumor biology, treatment patterns and compliance with therapy between men and women are needed to understand the underlying etiologies for the survival difference in TNBC.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Anderson WF
        • Jatoi I
        • Tse J
        • Rosenberg PS.
        Male breast cancer: a population-based comparison with female breast cancer.
        J Clin Oncol. 2010; 28: 232-239
        • Siegel RL
        • Miller KD
        • Jemal A.
        Cancer statistics, 2019.
        CA Cancer J Clin. 2019; 69: 7-34
        • Wang F
        • Shu X
        • Meszoely I
        • Pal T
        • Mayer IA
        • Yu Z
        • et al.
        Overall mortality after diagnosis of breast cancer in men vs women.
        JAMA Oncol. 2019; 5: 1589-1596
        • Anderson WF
        • Althuis MD
        • Brinton LA
        • Devesa SS.
        Is male breast cancer similar or different than female breast cancer?.
        Breast Cancer Res Treat. 2004; 83: 77-86
        • Perou CM
        • Sorlie T
        • Eisen MB
        • et al.
        Molecular portraits of human breast tumours.
        Nature. 2000; 406: 747-752
        • Diana A
        • Franzese E
        • Centonze S
        • et al.
        Triple-negative breast cancers: systematic review of the literature on molecular and clinical features with a focus on treatment with innovative drugs.
        Curr Oncol Rep. 2018; 20: 76
        • Howlader N
        • Altekruse SF
        • Li CI
        • et al.
        US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
        J Natl Cancer Inst. 2014; 106dju055
        • Bauer KR
        • Brown M
        • Cress RD
        • Parise CA
        • Caggiano V.
        Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
        Cancer. 2007; 109: 1721-1728
        • Dent R
        • Trudeau M
        • Pritchard KI
        • et al.
        Triple-negative breast cancer: clinical features and patterns of recurrence.
        Clin Cancer Res. 2007; 13: 4429-4434
        • Cardoso F
        • Bartlett JMS
        • Slaets L
        • et al.
        Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
        Ann Oncol. 2018; 29: 405-417
      1. American College of Surgeons. National Cancer Database [Available at: https://www.facs.org/quality-programs/cancer/ncdb, January 2021.

        • Gnerlich JL
        • Deshpande AD
        • Jeffe DB
        • Seelam S
        • Kimbuende E
        • Margenthaler JA.
        Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration.
        Ann Surg Oncol. 2011; 18: 1837-1844
        • Miao H
        • Verkooijen HM
        • Chia KS
        • et al.
        Incidence and outcome of male breast cancer: an international population-based study.
        J Clin Oncol. 2011; 29: 4381-4386
        • El-Tamer MB
        • Komenaka IK
        • Troxel A
        • et al.
        Men with breast cancer have better disease-specific survival than women.
        Arch Surg (Chicago, Ill: 1960). 2004; 139: 1079-1082
        • Piscuoglio S
        • Ng CK
        • Murray MP
        • et al.
        The genomic landscape of male breast cancers.
        Clin Cancer Res. 2016; 22: 4045-4056
        • Pritzlaff M
        • Summerour P
        • McFarland R
        • et al.
        Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
        Breast Cancer Res Treat. 2017; 161: 575-586
        • Yadav S
        • Couch FJ.
        Germline genetic testing for breast cancer risk: the past, present, and future.
        Am Soc Clin Oncol Educ Book. 2019; : 61-74
        • Ibrahim M
        • Yadav S
        • Ogunleye F
        • Zakalik D.
        Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
        BMC Cancer. 2018; 18: 179
        • Williams BG
        • Iredale R
        • Brain K
        • France E
        • Barrett-Lee P
        • Gray J.
        Experiences of men with breast cancer: an exploratory focus group study.
        Br J Cancer. 2003; 89: 1834-1836
        • Ruddy KJ
        • Winer EP.
        Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship.
        Ann Oncol. 2013; 24: 1434-1443
        • Midding E
        • Halbach SM
        • Kowalski C
        • Weber R
        • Würstlein R
        • Ernstmann N.
        Men with a "woman's disease": stigmatization of male breast cancer patients-a mixed methods analysis.
        Am J Men's Health. 2018; 12: 2194-2207
        • Mosca L
        • Barrett-Connor E
        • Wenger NK.
        Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes.
        Circulation. 2011; 124: 2145-2154
        • van Hoesel QG
        • Steerenberg PA
        • Dormans JA
        • de Jong WH
        • de Wildt DJ
        • Vos JG.
        Time-course study on doxorubicin-induced nephropathy and cardiomyopathy in male and female LOU/M/Wsl rats: lack of evidence for a causal relationship.
        J Natl Cancer Inst. 1986; 76: 299-307
        • Moulin M
        • Piquereau J
        • Mateo P
        • et al.
        Sexual dimorphism of doxorubicin-mediated cardiotoxicity.
        Circ Heart Fail. 2015; 8: 98-108
        • Yadav S
        • Karam D
        • Bin Riaz I
        • et al.
        Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century.
        Cancer. 2020; 126: 26-36
        • Massarweh SA
        • Sledge GW
        • Miller DP
        • McCullough D
        • Petkov VI
        • Shak S.
        Molecular characterization and mortality from breast cancer in men.
        J Clin Oncol. 2018; 36: 1396-1404
        • Muir D
        • Kanthan R
        • Kanthan SC.
        Male versus female breast cancers. A population-based comparative immunohistochemical analysis.
        Arch Pathol Lab Med. 2003; 127: 36-41
        • Sineshaw HM
        • Freedman RA
        • Ward EM
        • Flanders WD
        • Jemal A.
        Black/White disparities in receipt of treatment and survival among men with early-stage breast cancer.
        J Clin Oncol. 2015; 33: 2337-2344
        • Crew KD
        • Neugut AI
        • Wang X
        • et al.
        Racial disparities in treatment and survival of male breast cancer.
        J Clin Oncol. 2007; 25: 1089-1098
        • Newman LA
        • Griffith KA
        • Jatoi I
        • Simon MS
        • Crowe JP
        • Colditz GA.
        Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status.
        J Clin Oncol. 2006; 24: 1342-1349
        • Du W
        • Simon MS.
        Racial disparities in treatment and survival of women with stage I-III breast cancer at a large academic medical center in metropolitan Detroit.
        Breast Cancer Res Treat. 2005; 91: 243-248
        • Ko NY
        • Hong S
        • Winn RA
        • Calip GS.
        Association of insurance status and racial disparities with the detection of early-stage breast cancer.
        JAMA Oncol. 2020; 6: 385-392
        • Tammemagi CM
        • Nerenz D
        • Neslund-Dudas C
        • Feldkamp C
        • Nathanson D.
        Comorbidity and survival disparities among black and white patients with breast cancer.
        JAMA. 2005; 294: 1765-1772
        • Gierach GL
        • Burke A
        • Anderson WF.
        Epidemiology of triple negative breast cancers.
        Breast Dis. 2010; 32: 5-24
        • Amend K
        • Hicks D
        • Ambrosone CB.
        Breast cancer in African-American women: differences in tumor biology from European-American women.
        Cancer Res. 2006; 66: 8327-8330
      2. Bureau USC. Quickfacts United States 2018 [Available at: https://www.census.gov/quickfacts/fact/table/US/PST045218, January 2021.

        • Davis Lynn BC
        • Rosenberg PS
        • Anderson WF
        • Gierach GL
        Black–White breast cancer incidence trends: effects of ethnicity.
        J Natl Cancer Inst. 2018; 110: 1270-1272
        • Siddharth S
        • Sharma D.
        Racial disparity and triple-negative breast cancer in african-american women: a multifaceted affair between obesity, biology, and socioeconomic determinants.
        Cancers. 2018; 10: 514
        • Boffa DJ
        • Rosen JE
        • Mallin K
        • et al.
        Using the National Cancer Database for outcomes research: a review.
        JAMA Oncol. 2017; 3: 1722-1728